Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Ibrutinib and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab for Patients in NCRI FLAIR Study with Previously Untreated CLL: Assessment of Mutational Landscape of Patients at Baseline and Prognostic Impact

Blood (2023) 142 (Supplement 1): 4637.

https://doi.org/10.1182/blood-2023-180527

Published: 2023

Journal Articles

Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients

Blood (2023) 142 (Supplement 1): 4636.

https://doi.org/10.1182/blood-2023-188597

Published: 2023

Journal Articles

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

Blood (2022) 140 (Supplement 1): 231–233.

https://doi.org/10.1182/blood-2022-170463

Published: 2022

Journal Articles

Variable Expression of Therapeutic Antibody Targets May Have Implications for Efficacy of Therapy in Myeloma and Waldenstrom Macroglobulinaemia

Ruth M de Tute, MSc, Jane Shingles, PhD, Andy C. Rawstron, PhD, Roger G Owen, MD

Blood (2014) 124 (21): 3425.

https://doi.org/10.1182/blood.V124.21.3425.3425

Published: 2014

Journal Articles

Insights Into The Natural History Of Paroxysmal Nocturnal Hemoglobinuria (PNH): Analysis Of The Presenting Clinical, Haematological and Flow Cytometric Features Of 705 Patients Leads To Improved Classification and Prediction Of Clinical Course

Stephen John Richards, PhD, Richard Kelly, MD, Anita Hill, MBChB, PhD, Anita Dickinson, MSc, Fiona Cullen, MSc, Jane Shingles, PhD, Matthew Cullen, MSc, Peter Hillmen, MB ChB, PhD

Blood (2013) 122 (21): 3718.

https://doi.org/10.1182/blood.V122.21.3718.3718

Published: 2013

Journal Articles

Differential Protein Expression in MBL and CLL: LAIR1 Is a Powerful Surface Marker for Identifying Cases with Adverse Cellular Features.

Andy C Rawstron, BSc, PhD, Darren J Newton, Ruth M. de Tute, Jane Shingles, Fiona L Bennett, Paul A.S. Evans, Sheila J.M. O’Connor, Andrew S Jack, Peter Hillmen

Blood (2008) 112 (11): 2076.

https://doi.org/10.1182/blood.V112.11.2076.2076

Published: 2008

NARROW

Ibrutinib and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab for Patients in NCRI FLAIR Study with Previously Untreated CLL: Assessment of Mutational Landscape of Patients at Baseline and Prognostic Impact

Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

Variable Expression of Therapeutic Antibody Targets May Have Implications for Efficacy of Therapy in Myeloma and Waldenstrom Macroglobulinaemia

Insights Into The Natural History Of Paroxysmal Nocturnal Hemoglobinuria (PNH): Analysis Of The Presenting Clinical, Haematological and Flow Cytometric Features Of 705 Patients Leads To Improved Classification and Prediction Of Clinical Course

Differential Protein Expression in MBL and CLL: LAIR1 Is a Powerful Surface Marker for Identifying Cases with Adverse Cellular Features.

Email alerts

ASH Publications

American Society of Hematology

Ibrutinib and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab for Patients in NCRI FLAIR Study with Previously Untreated CLL: Assessment of Mutational Landscape of Patients at Baseline and Prognostic Impact

Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

Variable Expression of Therapeutic Antibody Targets May Have Implications for Efficacy of Therapy in Myeloma and Waldenstrom Macroglobulinaemia

Insights Into The Natural History Of Paroxysmal Nocturnal Hemoglobinuria (PNH): Analysis Of The Presenting Clinical, Haematological and Flow Cytometric Features Of 705 Patients Leads To Improved Classification and Prediction Of Clinical Course

Differential Protein Expression in MBL and CLL: LAIR1 Is a Powerful Surface Marker for Identifying Cases with Adverse Cellular Features.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only